Viewing Study NCT01256905


Ignite Creation Date: 2025-12-25 @ 3:18 AM
Ignite Modification Date: 2025-12-31 @ 11:46 PM
Study NCT ID: NCT01256905
Status: WITHDRAWN
Last Update Posted: 2021-08-23
First Post: 2010-12-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Sponsor: NYU Langone Health
Organization:

Study Overview

Official Title: Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Status: WITHDRAWN
Status Verified Date: 2021-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: PI departure from institution
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Armodafinil
Brief Summary: The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced Parkinson's disease (PD) and Lewy body disease (LBD).
Detailed Description: The main aims of this study are:

1\. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia thalamocortical network, measured through the Electroencephalography (EEG) frequency analysis, are ameliorated by armodafinil.

Our main hypothesis is that armodafinil can restore the attention and improve cognitive disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: